Search

Your search keyword '"Kluin-Nelemans H"' showing total 299 results
Start Over Author "Kluin-Nelemans H"
299 results on '"Kluin-Nelemans H"'

3. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts

Author

Valent, P., Akin, C., Hartmann, K., Nilsson, G., Reiter, A., Hermine, O., Sotlar, K., Sperr, W. R., Escribano, L., George, T. I., Kluin-Nelemans, H. C., Ustun, C., Triggiani, M., Brockow, K., Gotlib, J., Orfao, A., Kovanen, P. T., Hadzijusufovic, E., Sadovnik, I., Horny, H. -P., Arock, M., Schwartz, L. B., Frank Austen, K., Metcalfe, D. D., Galli, S. J., Austrian Science Fund, National Institutes of Health (US), United States-Israel Binational Science Foundation, and Stanford University

Subjects
mastocytosis, tryptase, KIT, Cell Differentiation, History, 19th Century, Review, History, 20th Century, histamine, History, 21st Century, humanities, Immunity, Innate, Disease Models, Animal, Histamine, IgE receptor, Mast cell activation, Mastocytosis, Tryptase, Allergy and Immunology, mast cell activation, Hypersensitivity, Animals, Humans, Mast Cells, Molecular Targeted Therapy, Precision Medicine, Immunosuppressive Agents
Abstract

© The author(s)., The origin and functions of mast cells (MCs) have been debated since their description by Paul Ehrlich in 1879. MCs have long been considered 'reactive bystanders' and 'amplifiers' in inflammatory processes, allergic reactions, and host responses to infectious diseases. However, knowledge about the origin, phenotypes and functions of MCs has increased substantially over the past 50 years. MCs are now known to be derived from multipotent hematopoietic progenitors, which, through a process of differentiation and maturation, form a unique hematopoietic lineage residing in multiple organs. In particular, MCs are distinguishable from basophils and other hematopoietic cells by their unique phenotype, origin(s), and spectrum of functions, both in innate and adaptive immune responses and in other settings. The concept of a unique MC lineage is further supported by the development of a distinct group of neoplasms, collectively referred to as mastocytosis, in which MC precursors expand as clonal cells. The clinical consequences of the expansion and/or activation of MCs are best established in mastocytosis and in allergic inflammation. However, MCs have also been implicated as important participants in a number of additional pathologic conditions and physiological processes. In this article, we review concepts regarding MC development, factors controlling MC expansion and activation, and some of the fundamental roles MCs may play in both health and disease. We also discuss new concepts for suppressing MC expansion and/or activation using molecularly-targeted drugs., P.V. was supported by the Austrian Science Fund (FWF), grants F4701-B28, F4704-B28 and P32470-B. DDM is supported by the Division of Intramural Research, NIAID. SJG's research is supported by the NIH, USA, the US-Israel Binational Foundation, and the Department of Pathology and the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, CA.

Published
2020

9. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis

Author

Valent, P., Escribano, L., Broesby-Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, J. N. G., Kristensen, T., Butterfield, J. H., Triggiani, M., Alvarez-Twose, I., Reiter, A., Sperr, W. R., Sotlar, K., Yavuz, S., Kluin-Nelemans, H. C., Hermine, O., Radia, D., van Doormaal, J. J., Gotlib, J., Orfao, A., Siebenhaar, F., Schwartz, L. B., Castells, M., Maurer, M., Horny, H.-P., Akin, C., Metcalfe, D. D., and Arock, M.

Published
2014
Full Text
View/download PDF

11. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal

Author

Valent, P., Sotlar, K., Sperr, W. R., Escribano, L., Yavuz, S., Reiter, A., George, T. I., Kluin-Nelemans, H. C., Hermine, O., Butterfield, J. H., Hägglund, H., Ustun, C., Hornick, J. L., Triggiani, M., Radia, D., Akin, C., Hartmann, K., Gotlib, J., Schwartz, L. B., Verstovsek, S., Orfao, A., Metcalfe, D. D., Arock, M., and Horny, H.-P.

Published
2014
Full Text
View/download PDF

13. PREDICTION OF RELAPSE BY STANDARDIZED IG‐BASED ALLEL‐SPECIFIC QPCR, DDPCR AND AMPLICON NGS FOR MRD MONITORING IN MANTLE CELL LYMPHOMA: A COMPARATIVE ANALYSIS BY THE EU‐MCL NETWORK

Author

Pott, C., primary, Macintyre, E., additional, Delfau, M.‐H., additional, Weiß, A., additional, Schilhabel, A., additional, Soehlbrand, A., additional, Kehden, B., additional, Darzentas, N., additional, Kotrova, M., additional, Schoen, F., additional, Ribrag, V., additional, Brueggemann, M., additional, Villarese, P., additional, Dreyling, M., additional, Hermine, O., additional, Kluin‐Nelemans, H., additional, Jiang, L., additional, and Hoster, E., additional

Published
2021
Full Text
View/download PDF

19. Treatment of Older Patients with Mantle-Cell Lymphoma

Author

Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., Coiffier, B., Forstpointner, R., Tilly, H., Kanz, L., Feugier, P., Szymczyk, M., Hallek, M., Kremers, S., Lepeu, G., Sanhes, L., Zijlstra, J. M., Bouabdallah, R., Lugtenburg, P. J., Macro, M., Pfreundschuh, M., Procházka, V., Di Raimondo, F., Ribrag, V., Uppenkamp, M., André, M., Klapper, W., Hiddemann, W., Unterhalt, M., and Dreyling, M. H.

Published
2012
Full Text
View/download PDF

26. Minimal residual disease (MRD) is a predictor of clinical outcome in elderly patients with MCL and identifies patients with long lasting remissions after R-CHOP or R-FC induction followed by maintenance with rituximab or IFN: first results of the randomized EU-MCL elderly trial: V115

Author

Pott, C., Delfau-Larue, M.-H., Beldjord, K., Böttcher, S., Macintyre, E., Asnafi, V., Siebert, R., Klapper, W., Unterhalt, M., Kneba, M., Hiddemann, W., Hermine, O., Kluin-Nelemans, H., Dreyling, M., and Hoster, E.

Published
2011

36. Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria

Author

Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin-Nelemans, H. C., Hamdy, N. A. T., Lortholary, O., Robyn, J., van Doormaal, J., Sotlar, K., Hauswirth, A. W., Arock, M., Hermine, O., Hellmann, A., Triggiani, M., Niedoszytko, M., Schwartz, L. B., Orfao, A., Horny, H.-P., and Metcalfe, D. D.

Published
2007

39. Conut score as a tool for early detection of poor nutritional status in advances forms of SM

Author

Gruchala-Niedoszytko, M., Gorska, A., Nedoszytko, B., Lange, M., Niedoszytko, M., Rabenhorst, A., Sperr, W., Elberink, Oude J., Gleixner, K., Brazzelli, V., Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Hartmann, K., Valent, P., and Arock, M.

Published
2019

42. Hypereosinophilia: a diagnostic challenge

Author

Balkum, M., Kluin-Nelemans, H., Jaap J. van Hellemond, Genderen, P. J. J., Wismans, P. J., and Medical Microbiology & Infectious Diseases

Published
2018

43. The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases

Author

Bonifazi, F, De Vivo, A, Rosti, G, Guilhot, F, Guilhot, J, Trabacchi, E, Hehlmann, R, Hochhaus, A, Shepherd, P, Steegmann, J, Kluin-Nelemans, H, Thaler, J, Simonsson, B, Louwagie, A, Reiffers, J, Mahon, F, Montefusco, E, Alimena, G, Hasford, J, Richards, S, Saglio, G, Testoni, N, Martinelli, G, Tura, S, and Baccarani, M

Published
2016

44. Cardiac Disease and Lifestyle Risk Factors Following Hodgkin Lymphoma: An EORTC Lymphoma Group and GELA Follow-Up Study

Author

Maraldo, M.V., primary, Giusti, F., additional, van der Kaaij, M., additional, Henry-Amar, M., additional, Aleman, B., additional, Raemaekers, J., additional, Meijnders, P.J., additional, Moser, E.C., additional, Kluin-Nelemans, H., additional, Spina, M., additional, Ferme, C., additional, Fortpied, C., additional, and Specht, L., additional

Published
2017
Full Text
View/download PDF

45. MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND a RITUXIMAB-LENALIDOMIDE MAINTENANCE

Author

Ribrag, V., primary, Feugier, P., additional, Doorduijn, J., additional, Delfau-Larue, M., additional, Hermine, O., additional, Kluin-Nelemans, H., additional, Dasilva, M., additional, Lopez-Hernandez, A., additional, Walewski, J., additional, Szymczyk, M., additional, Pott, C., additional, Homburg, C., additional, Van der Velden, V., additional, Gameiro, P., additional, Garcia-Sanz, R., additional, Ladetto, M., additional, van Krieken, H., additional, Cabeçadas, J., additional, Rymkiewicz, G., additional, Klapper, W., additional, Hoster, E., additional, Le Gouill, S., additional, and Dreyling, M., additional

Published
2017
Full Text
View/download PDF

46. Age at disease onset has a major impact on clinical characteristics and course of mastocytosis

Author

Rabenhorst, A., Sperr, W., Elberink, J. Oude, Lange, M., Gleixner, K., Brazzelli, V., Fontana, E., Vos, B., Gorska, A., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Kilbertus, A., Sabato, V., Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, A. Belloni, Merante, S., Niedoszytko, M., Kluin-Nelemans, H., Valent, P., Hartmann, K., Rabenhorst, A., Sperr, W., Elberink, J. Oude, Lange, M., Gleixner, K., Brazzelli, V., Fontana, E., Vos, B., Gorska, A., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Kilbertus, A., Sabato, V., Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, A. Belloni, Merante, S., Niedoszytko, M., Kluin-Nelemans, H., Valent, P., and Hartmann, K.

Published
2017

47. POOLED SURVIVAL ANALYSIS OF MIDOSTAURIN CLINICAL STUDY DATA (D2201+A2213) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS COMPARED WITH HISTORICAL CONTROLS

Author

Reiter, A., Kluin-Nelemans, H. C., George, T., Akin, C., DeAngelo, D. J., Hermine, O., Awan, F., Hexner, E., Mauro, M., Schwaab, J., Jawhar, M., Sternberg, D., Berkowitz, N., Niolat, J., Labed, A. Huntsman, Hartmann, K., Horny, H-P., Valent, P., Gotlib, J., Reiter, A., Kluin-Nelemans, H. C., George, T., Akin, C., DeAngelo, D. J., Hermine, O., Awan, F., Hexner, E., Mauro, M., Schwaab, J., Jawhar, M., Sternberg, D., Berkowitz, N., Niolat, J., Labed, A. Huntsman, Hartmann, K., Horny, H-P., Valent, P., and Gotlib, J.

Published
2017

48. Impact of allergic disorders and anaphylaxis in mastocytosis: Preliminary data from a study of the European Competence Network on Mastocytosis (ECNM) registry

Author

Niedoszytko, M., Gorska, A., Nedoszytko, B., Rabenhorst, A., Sperr, W., Elberink, Oude J., Lange, M., Gleixner, K., Brazzelli, V, Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V, Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Valent, P., Hartmann, K., Niedoszytko, M., Gorska, A., Nedoszytko, B., Rabenhorst, A., Sperr, W., Elberink, Oude J., Lange, M., Gleixner, K., Brazzelli, V, Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V, Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Valent, P., and Hartmann, K.

Published
2017

49. The body mass index is an indicator of advanced systemic mastocytosis: preliminary results from a registry project of the European Competence Network on Mastocytosis (ECNM) registry

Author

Gorska, A., Gruchala-Niedoszytko, M., Niedoszytko, M., Rabenhorst, A., Sperr, W., Elberink, Oude J., Lange, M., Gleixner, K., Brazzelli, V, Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V, Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Valent, P., Hartmann, K., Gorska, A., Gruchala-Niedoszytko, M., Niedoszytko, M., Rabenhorst, A., Sperr, W., Elberink, Oude J., Lange, M., Gleixner, K., Brazzelli, V, Fontana, E., Vos, B., Reiter, A., Schwaab, J., Zanotti, R., Bonadonna, P., Triggiani, M., Gotlib, J., Doubek, M., Jakob, T., Fuchs, D., Sabato, V, Zink, A., Bretterklieber, A., Jaekel, N., Sotlar, K., Horny, H., Fortina, Belloni A., Merante, S., Kluin-Nelemans, H., Valent, P., and Hartmann, K.

Published
2017

50. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice

Author

Ustun, C., primary, Arock, M., additional, Kluin-Nelemans, H. C., additional, Reiter, A., additional, Sperr, W. R., additional, George, T., additional, Horny, H.-P., additional, Hartmann, K., additional, Sotlar, K., additional, Damaj, G., additional, Hermine, O., additional, Verstovsek, S., additional, Metcalfe, D. D., additional, Gotlib, J., additional, Akin, C., additional, and Valent, P., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results